Related Experiment Videos
Redirected cellular cytotoxicity employing bispecific antibodies and other multifunctional binding proteins
L M Weiner1, R K Alpaugh, M von Mehren
1Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA. lm_weiner@fccc.edu
Abstract:
Commencing with the discovery and characterization of bispecific antibodies, numerous investigations have shown that such antibodies are capable of redirecting cellular cytotoxicity. Clinical trials testing diverse strategies, including those targeting CD16-expressing effector cells, have been conducted or are in progress. This manuscript reviews our clinical trials efforts with bispecific antibodies and describes our experience employing multi-functional binding proteins containing tumor-targeting antibody Fab fragments linked to bacterial superantigens, such as staphylococcal enterotoxin A.
Insights
Bispecific antibodies redirect cellular cytotoxicity, with clinical trials exploring strategies like targeting CD16 effector cells. This review details clinical efforts using multi-functional binding proteins with tumor-targeting fragments and bacterial superantigens.
Area of Science:
- Immunology
- Oncology
- Biotechnology
Background:
- Bispecific antibodies are engineered proteins that bind to two different targets simultaneously.
- These antibodies have demonstrated the ability to redirect cellular cytotoxicity, a key mechanism in immune response against target cells.
- Clinical investigations have explored various bispecific antibody strategies, including those that engage CD16-expressing effector cells.
Purpose of the Study:
- To review clinical trial efforts involving bispecific antibodies.
- To describe the experience with multi-functional binding proteins.
- To highlight the use of tumor-targeting antibody fragments linked to bacterial superantigens.
Main Methods:
- Review of clinical trial data and experiences.
- Characterization of bispecific antibodies and their mechanisms.
- Development and application of multi-functional binding proteins, specifically linking antibody Fab fragments to bacterial superantigens like staphylococcal enterotoxin A.
Main Results:
- Bispecific antibodies have shown efficacy in redirecting cellular cytotoxicity.
- Clinical trials targeting CD16-expressing effector cells are ongoing or completed.
- Multi-functional binding proteins combining tumor-targeting and superantigen domains represent a viable therapeutic strategy.
Conclusions:
- Bispecific antibodies are a promising therapeutic modality for redirecting cellular cytotoxicity.
- Clinical trials continue to evaluate diverse bispecific antibody strategies, including those engaging effector cells.
- The use of engineered proteins linking tumor-targeting fragments with bacterial superantigens offers a novel approach in cancer immunotherapy.